This study is looking at how a special type of scan, called fluciclovine (18F) PET, can help doctors manage prostate cancer. This is for men who have had their prostate cancer come back (biochemical recurrence) after treatment, and whose previous PSMA (Prostate-Specific Membrane Antigen) PET scans didn't clearly show where the cancer was. The study wants to see if the fluciclovine (18F) PET scan changes the treatment plan for these patients. To join, you must be a male aged 18 or older with prostate cancer recurrence and a recent negative or unclear PSMA PET scan. The main goal is to measure how many participants have a change in their treatment plan after getting the fluciclovine (18F) PET/CT scan, which will be measured within 30 days of the scan. The current status of this study is unclear, and it plans to enroll 142 participants.

Study design

This is a prospective, multi-institutional study that plans to enroll 142 participants. It is not specified if it is randomized or blinded.

What's involved

Participants will receive an intravenous injection of fluciclovine (18F) and undergo a PET/CT scan. This scan will occur at least 24 hours after a piflufolastat (18F) scan, but within 30 days.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, change in management, is measured within 30 calendar days after the fluciclovine (18F) scan.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.